检索结果-南通市图书馆

Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy

World Journal of Gastroenterology 2013年第2期19卷 249-257页

作者： Takanori Hosokawa Masayuki Kurosaki Kaoru Tsuchiya Shuya Matsuda Masaru Muraoka Yuichiro Suzuki Nobuharu Tamaki Yutaka Yasui Toru Nakata Takashi Nishimura Shoko Suzuki Ken Ueda Hiroyuki Nakanishi Jun Itakura Yuka Takahashi namiki izumi Division of Gastroenterology and Hepatology Musashino Red Cross HospitalTokyo 180-8610Japan

AIM:To evaluate whether metabolic factors are related to distant recurrence of hepatocellular carcinoma(HCC) and survival after curative ***:This retrospective study included 344 patients whose HCC was treated curatively by radiofrequency ablation(RFA) *** mean age was 67.6 years and the mean observation period was 4.04 *** etiological background of liver disease was hepatitis B virus infection in 30,hepatitis C virus infection in 278,excessive alcohol drinking in 9,and other in 27 *** Child-Pugh classification grade was A(n = 307) or B(n = 37).The number of HCC nodules was one in 260,two in 61,and three in 23 *** surveillance of HCC recurrence after curative therapy with RFA,patients were radiologically evaluated every 3 *** associated with distant recurrence of HCC or survival were ***:Inadequate maintenance of blood glucose in diabetic patients was associated with higher incidence of distant *** 1-,2-,and 3-year recurrence rates were significantly higher in diabetic patients with inadequate maintenance of blood glucose compared with the others:50.6% vs 26.8%,83.5% vs 54.4%,and 93.8% vs 73.0%,respectively(P = 0.0001).Inadequate maintenance of blood glucose was an independent predictor of distant recurrence [adjusted relative risk 1.97(95%CI,1.33-2.91),(P = 0.0007)] after adjustment for other risk factors,such as number of HCC nodules [2.03(95%CI,1.51-2.73),P < 0.0001] and initial level of serum alpha fetoprotein(AFP) [1.43(95%CI,1.04-1.97),P = 0.028].Obesity was not an independent predictor of *** incidence of distant recurrence did not differ between diabetic patients with adequate maintenance of blood glucose and non-diabetic *** 232 patients who had HCC recurrence,138 had a second *** 1-,2-,and 3-year rates of second recurrence were significantly higher in diabetic patients with inadequate maintenance of blood glucose than in the others:9.0% vs 5.9%,53.1

关键词： Hyperglycemia Hepatocellular carcinoma Recurrence Radio frequency ablation Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development

引用

World Journal of Hepatology 2015年第27期7卷 2757-2764页

作者： Satoshi Shakado Shotaro Sakisaka Kazuaki Chayama Takeshi Okanoue Joji Toyoda namiki izumi Akihiro Matsumoto Tetsuo Takehara Akio Ido Yoichi Hiasa Kentaro Yoshioka Hideyuki Nomura Yoshiyuki Ueno Masataka Seike Hiromitsu Kumada Department of Gastro-enterology and Medicine Faculty of Medicine Fukuoka University Department of Gastroenterology and Metabolism Applied Life Sciences Graduate School of Biome-dical and Health SciencesHiroshima University Center of Gastroenterology and Hepatology Saiseikai Suita Hospital Department of Gastroenterology and Hepatology Sapporo Kousei Hospital Department of Gastroenterology and Hepatology Musashino Red-Cross Hospital Department of Medicine Shinshu University School of Medicine Department of Gastroenterology and Hepa-tology Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology Kagoshima University Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Department of Liver Biliary Tract and Pancreas Diseases Fujita Health University the Center for Liver Disease Shin-Kokura Hospital Department of Gastroenterology Yamagata University Department of Gastroenterology Faculty of Medicine Oita University Department of Hepatology Toranomon Hospital

AIM: To investigate risk factors for development of hepatocellular carcinoma(HCC) in patients with hepatitis C virus-related liver cirrhosis(LC-C).METHODS: To evaluate the relationship between clinical factors including virological response and the development of HCC in patients with LC-C treated with interferon(IFN) and ribavirin, we conducted a multicenter, retrospective study in 14 hospitals in Japan. All patients had compensated LC-C with clinical or histological data available. HCC was diagnosed by the presence of typical hypervascular characteristics on computed tomography and/or magnetic resonance ***: HCC was diagnosis in 50(21.6%) of 231 LC-C patients during a median observation period of 3.8 years after IFN and ribavirin therapy. Patients who developed HCC were older(P = 0.018) and had higher serum levels of pretreatment alpha-fetoprotein(AFP)(P = 0.038). Multivariate analysis revealed the following independent risk factors for HCC development: history of treatment for HCC [P < 0.001, odds ratio(OR) = 15.27, 95%CI: 4.98-59.51], AFP levels of ≥ 10 ng/m L(P = 0.009, OR = 3.89, 95%CI: 1.38-11.94), and des-γ-carboxy prothrombin(DCP) levels of ≥ 40 m AU/mL at 24 wk after the completion of IFN and ribavirin therapy(P < 0.001, OR = 24.43, 95%CI: 4.11-238.67).CONCLUSION: We suggested that the elevation of AFP and DCP levels at 24 wk after the completion of IFN and ribavirin therapy were strongly associated with the incidence of HCC irrespective of virological response among Japanese LC-C patients.

关键词： Des-γ-carboxy prothrombin Hepatocellular carcinoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

慢性乙型肝炎患者144周治疗期间未发现丙酚替诺福韦耐药

慢性乙型肝炎患者144周治疗期间未发现丙酚替诺福韦耐药

引用

第十届全国疑难及重症肝病大会

作者： Henry Lik-Yuen Chan Patrick Marcellin Calvin Q.Pan Andrea L Cathcart Neeru Bhardwaj Yang Liu Bandta Parhy Eric Zhou David Hsieh Silvia Chang Ross Martin Becket Feierbach Hongmei Mo Anuj Gaggar John F Flaherty Shalimar namiki izumi Young-Suk Lim The Chinese University of Hong Kong

背景在2项评价丙酚替诺福韦(TAF)或富马酸替诺福韦二吡呋酯(TDF)用于HBeAg+或HBeAg-慢性乙型肝炎初治或经治成人患者时的3期临床研究(GS-US-320-0108,GS-US-320-0110)中进行了累积耐药性分析。方法患者按照2:1的比例进行随机分组,并按照...

背景在2项评价丙酚替诺福韦(TAF)或富马酸替诺福韦二吡呋酯(TDF)用于HBeAg+或HBeAg-慢性乙型肝炎初治或经治成人患者时的3期临床研究(GS-US-320-0108,GS-US-320-0110)中进行了累积耐药性分析。方法患者按照2:1的比例进行随机分组,并按照HBV DNA水平和治疗状态进行分层接受TAF

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer： implications for clinical practice

引用

Asian Journal of Andrology 2017年第2期19卷 143-148页

作者： Atsushi Mizokami Kouji izumi Hiroyuki Konaka Yasuhide Kitagawa Yoshifumi Kadono Kazutaka Narimoto Takahiro Nohara Amit K Bahl Mikio namiki Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science 13-1 Takaramachi Kanazawa 920-8640 Japan Bristol Haematology and Oncology Centre University Hospitals Bristol Bristol BS2 8ED UK

Availability of novel hormonal therapies as well as docetaxel and cabazitaxel treatment for metastatic castration-resistant prostate cancer （CRPC） has changed the outlook for this group of patients with improvements in progression-free survival and overall survival. Physicians often diagnose the progression of prostate cancer using serum prostate-specific antigen （PSA）. However, serum PSA is not always correlated with the clinical status in CRPC. To evaluate the PSA dynamics with greater precision, understanding of the control of PSA and of the mechanisms of development of CRPC is needed. Moreover, it is necessary to use new hormonal therapies with an appropriate timing to optimally improve the prognosis and the QOL of the patients. In the present review, we ascertain the PSA dynamics and the mechanisms of the development of CRPC to assist in optimal utilization of the new treatments for mCRPC.

关键词： castration-resistant prostate cancer new hormonal therapy prostate-specific antigen

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Optimal treatment for castration-resistant prostate cancer

引用

Asian Journal of Andrology 2014年第3期16卷 498-498页

作者： Kouji izumi Mikio namiki Department of Integrative Cancer Therapy and Urology Kanazawa UniversityGraduate School of Medical Science Kanazawa Japan.

The review article of treatments for castration-resistant prostate cancer （CRPC） by Sartor and Gillessen describes available sequencing data in detail with outlines of each agent.~ Currently, the efficacy of docetaxel, radium-223, sipuleucel-T, abiraterone and enzalutamide （this is upcoming） as front-line agents and cabazitaxel, radium-223, abiraterone and enzalutamide as post-docetaxel agents have been confirmed by phase III randomized controlled trials （RCTs）. While the development of treatment options should be of great benefit to CRPC patients, physicians may need to pay attention to patient selection for each treatment as these agents have not been compared with one another by head-to-head RCT.

关键词： castration-resistant cancer pay attention

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan

引用

Asian Journal of Andrology 2014年第6期16卷 833-837页

作者： Yasuhide Kitagawa Kazuaki Machioka Hiroshi Yaegashi Kazufumi Nakashima Mitsuo Ofud Kouji izumi Satoru Ueno Yoshifumi Kadono Hiroyuki Konaka Atsushi Mizokami Mikio namiki Department of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa 920-8640 Japan

To clarify the recent trends in prostate-specific antigen （PSA） distribution in men in Japan, we analyzed the PSA distributions of men undergoing PSA-based population screening. We summarized the annual individual data of PSA-based population screening in Kanazawa, Japan, from 2000 to 2011, and analyzed baseline serum PSA values of the participants at the first population screening. Serum PSA distributions were estimated in all participants and those excluding prostate cancer patients according to age. From 2000 to 2011, 19 620 men participated aged 54-69 years old in this screening program. Mean baseline serum PSA level of all participants at the first screening was 2.64 ng m1-1 in 2000, and gradually decreased to approximately 1.30 ng ml-I in 2006. That of participants excluding prostate cancer patients was 1.46 ng m1-1 in 2000, and there was no remarkable change during the study period. The 95t＂ percentiles in the participants excluding prostate cancer patients detected at the first population screening of men aged 54-59, 60-64, and 65-69 years old were 2.90, 3.60, and 4.50 ng m1-1, respectively. After the commencement of population screening, the proportion of prostate cancer patients with high serum PSA levels decreased. However, there were no changes in serum PSA levels in men without prostate cancer. Age-specific PSA reference level of men without prostate cancer in Japan was similar to that in China and Korea.

关键词： age-specific prostate-specific antigen reference range prostate cancer prostate-specific antigen-based population screening serum prostate-specific antigen distribution

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

慢性HBV患者从富马酸替诺福韦二吡呋酯(TDF)转换为丙酚替诺福韦(TAF)1年后,骨骼和肾脏安全性出现改善

慢性HBV患者从富马酸替诺福韦二吡呋酯(TDF)转换为丙酚替诺福韦(T...

引用

第十届全国疑难及重症肝病大会

作者： Wai Kay Walter Seto Maria Buti namiki izumi Young-Suk Lim Jia-Horng Kao Adrian Streinu-Cercel Elena Nurmukhametova Xiaoli Ma Fehmi Tabak Maciej Jablkowski Vithika Suri John F.Flaherty Audrey H.Lau Anuj Gaggar Shuyuan Mo Cong Cheng Abhijit Chowdhury Scott K.Fung Wan-Long Chuang Edward Gane Queen Mary Hospital Hong Kong

背景第96周时TAF显示出不劣于TDF的疗效,且对骨骼和肾脏的影响较小。在双盲(DB)治疗时间延长一年的方案修订实施后,50%的患者能够继续接受DB治疗,其余患者在第96周时已经转换为开放标签(OL)TAF。本研究对比了随机分配至TDF治疗组的患者...

背景第96周时TAF显示出不劣于TDF的疗效,且对骨骼和肾脏的影响较小。在双盲(DB)治疗时间延长一年的方案修订实施后,50%的患者能够继续接受DB治疗,其余患者在第96周时已经转换为开放标签(OL)TAF。本研究对比了随机分配至TDF治疗组的患者在第96周时继续TDF治疗或转换为TAF治疗后,第96周至第144周的疗效和安全性。

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

病毒性肝炎:乙型肝炎和丁型肝炎-临床(治疗、新化合物、耐药性) 一项在HBeAg阴性、慢性乙型肝炎(CHB)患者中比较磷丙替诺福韦(TAF)与富马酸替诺福韦二吡呋酯(TDF)的3期研究:96周时疗效和安全性结果

病毒性肝炎:乙型肝炎和丁型肝炎-临床(治疗、新化合物、耐药性) ...

引用

第九届全国疑难及重症肝病大会

作者： Maurizia Brunetto Young Suk Lim Ed Gane Wai Kay Seto Marina Osipenko Sang Hoon Ahn Harry L.Janssen Akash Shukla Wan Long Chuang Huy Trinh Mustafa K.Celen John F.Flaherty Audrey H.Lau Anuj Gaggar Vithika Suri Neeru Bhardwaj Kyungpil Kim G Mani Subramanian Calvin Pan namiki izumi Patrick Marcellin Henry Chan Maria Buti University Hospital of Pisa Asan Medical Centre Erasmus Medical Center

背景和目的:TAF是替诺福韦(TFV)的一种新型前体药,在血浆中比TDF更稳定,增强了TFV进入肝细胞的给药,且循环TFV水平降低。这项在HBeAg阴性患者中比较TAF与TDF的随机双盲研究显示,之前在48周时,在HBV DNA小于29IU/mL的患者比例方面,TAF的...

背景和目的:TAF是替诺福韦(TFV)的一种新型前体药,在血浆中比TDF更稳定,增强了TFV进入肝细胞的给药,且循环TFV水平降低。这项在HBeAg阴性患者中比较TAF与TDF的随机双盲研究显示,之前在48周时,在HBV DNA小于29IU/mL的患者比例方面,TAF的疗效并不劣于TDF,且骨骼和肾脏影响改善。本文摘展示了96周治疗后的结果。方法:425例患者被随机分配到接受TAF 25mg QD(n=285)或TDF 300mg QD(n=140),且治疗144

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：